# ProKidney Corp. Class A (PROK) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $2.01, market value $802 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). ProKidney Corp. Class A reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 980.9×**. Each dollar of revenue is priced at 980.9×, a level that requires very high margins or very fast growth to justify.
- **Free-cash-flow yield: -19.9%** (5-yr avg -18.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 6.8%**. 6.8% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on assets: -25.1%**. Each dollar of assets produces -25.1% of profit.

## Growth
- **Revenue growth (1 yr): 1075.0%**. Revenue grew 1075.0% over the last year.

## Financial health
- **Current ratio: 9.13** (quick 9.13). Current assets cover the next year's liabilities 9.13 times.
- **Altman Z-score: 8.90**. A Z-score of 8.90 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. ProKidney Corp. Class A does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -12.6%** (YTD -10.3%, 3-mo 11.7%). The shares are down 12.6% over twelve months including dividends.
- **From 52-week high: -42.2%** (54.6% above the low). Trading 42% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 70**. An RSI of 70 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 2.25** (volatility 83%). Beta of 2.25 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PROK · Page: https://foliofundamentals.com/stocks/prok

Not investment advice.